Connecticut Maxillofacial Surgeons, llc

Library

 

Looking for an expanded article on a topic referred to in our website? Want to download a follow-up document from one of our seminars? Hunting for information not found in the website?

Well, its quite possible you might find it here in our online library.

If you’re simply looking to DOWNLOAD a past CTMAX newsletter, You’ll Find them Here.

We’re still getting things organized and the shelves loaded, so its a little sparce at the moment. We’ll be adding more items soon.

Don’t see what you want? Contact us and let us help you find the information that you seek.


The NobelDirect 3.0 Implant

by Nobel BioCare

CTMAX is one of only a few surgical centers that is offering the NobelDirect 3.0 solid core implant.  This implant is ideal for placement in the anterior mandibular incisor region or other tight spaces.  Because of its solid core design, it can withstand the torque often required for placement in dense cortical bone.  By virtue of its one-piece design the abutment can be modified by the restorative dentist to accomodate a restoration of any size.  Immediate temporization is more often than not a possiblity followed by conventional techniques which are used to restore the implant.  Restoration is accomplished by conventional  impression taking and the use of a cemented restoration.

Download Article


NobelActive: “The Technical Story”

by Nobel Biocare

This article is an addendum to the NobelActive overview (A New Direction for Implants).  However, a more detailed description is given of the origins of the implant, its development and the specifics of what makes it so unique.  Close-ups of the implant design from both a surgical and prosthetic prospective are provided.  This implant is being routinely delivered to patients by us at CTMAX and the outcomes have been remarkably successful. It has filled a void where other implant designs simply would not work at the same time as providing natural platform switching in regions that demand maximum esthetic consideration.

Download Article


NobelActive: “Procedure and Placement”

by Nobel BioCare

This article is a reprint from Nobel BioCare describing the surgical procedures and placement as they relate to the new NobelActive Implant.  This implant is being routinely delivered to patients by us at CTMAX and the outcomes have been remarkably successful. It has filled a void where other implant designs simply would not work at the same time as providing natural platform switching in regions that demand maximum esthetic consideration.

Download Article


NobelActive: “A New Direction for Implants”

by Nobel BioCare

There has long been a void in the availability of an implant that will work effectively in tight spaces and where bone is often compromised.  The NobelActive has filled that void by providing a strong implant (capable of withstanding torque up to 70 N/CM), that compresses bone and provides necessary esthetic considerations to maximize gingival architecture.  Obtain an understanding of this implant by looking over this article outlining the features added in the design of this fixture that make it unique.  CTMAX is currently offering patients this fixture as a primary treatment modality especially in the anterior maxillary region where esthetic considerations are essential and bone density can often be compromised.

Download Article


NobelActive “Component Assortment Update”

by Nobel BioCare

This brochure is a brief update on the most available components for the NobelActive Implant.  The 4.5 esthetic abutment, modified impression copings and bridge components, new abutment retrieval tool and more are identified and discussed.  Furthermore, a two-year follow-up of the NobelActive tapered implant is presented at the end of the brochure.

The results show stable bone and soft tissue levels after two years in function and that the implant can be used under demanding treatment conditions, i.e., immediate loading.

Download Article


All-on 4: “An Alternative Surgical Technique for Full Arch Reconstruction”

by Nobel BioCare

This brochure is about everything “all-on-4”.  With a decade of experience the all-on-4 surgical technique and restorative option presents a less expensive and secure option for those looking for a complete maxillary or mandibular implant supported reconstruction.  CTMAX’s experience supports these statistics and further verifies that the surgical side of this treatment can be rendered with a brief recovery and an accelerated timeline to the finished restoration.  Immediate loading is possible in many cases.

Download Article


Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

by Dennis M. Black, Ph.D., Pierre D. Delmas, M.D., Ph.D., Richard Eastell, M.D., Ian R. Reid, M.D., Steven Boonen, M.D., Ph.D., Jane A. Cauley, Dr.P.H., Felicia Cosman, M.D., Peter Lakatos, M.D., Ph.D., Ping Chung Leung, M.D., Zulema Man, M.D., Carlos Mautalen, M.D., Peter Mesenbrink, Ph.D., Huilin Hu, Ph.D., John Caminis, M.D., Karen Tong, B.S., Theresa Rosario-Jansen, Ph.D., Joel Krasnow, M.D., Trisha F. Hue, M.P.H., Deborah Sellmeyer, M.D., Erik Fink Eriksen, M.D., D.M.Sc., and Steven R. Cummings, M.D.,  for the HORIZON Pivotal Fracture Trial

Background
A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.

Methods
In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes.

Results
Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001).

Conclusions
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, CT00049829.)

Download Article


“Three-Dimensional Ridge Augmentation with Xenograft and Recombinant Human Platelet-Derived Growth Factor-BB in Humans: Report of Two Cases”

by Massimo Simion, MD, DDS, Isabella Rocchietta, DDS, & Claudia Dellavia, DDS

A paper presenting two patients who underwent three-dimensional ridge augmentation using a xenograft in combination with recombinant human platelet-derived growth factor-BB (rhPDGF-BB).  The report suggests that the use of rhPDGF-BB in combination with a deproteinized bovine graft may have the potential to regenerated large three-dimensional alveolar defects in humans.

The article renders very nice photo and radiographich images of the post-treatment ridge forms and demonstrates, at least on two patients with limited follow-up, that vertical ridge augmentation in the mandibular arch may be possible under these special conditions.

Download Article


“Surgical and Orthodontic Management of Impacted Maxillary Canines”

by Vincent G. Kokich, DDS, MSD

This landmark article covers a contemporary approach to the exposure and management of the impacted maxillary canine.  The concept of allowing for self eruption after exposure of the palatally impacted is discussed along with the surgical recommendations for this approach.  Various positions of canine impaction are covered, classified and reviewed as to how one might best approach their recovery.

Download Article


“Three-Dimensional Ridge Augmentation with Xenograft and Recombinant Human Platelet-Derived Growth Factor-BB in Humans: Report of Two Cases”

by Massimo Simion, MD, DDS, Isabella Rocchietta, DDS, & Claudia Dellavia, DDS

A paper presenting two patients who underwent three-dimensional ridge augmentation using a xenograft in combination with recombinant human platelet-derived growth factor-BB (rhPDGF-BB).  The report suggests that the use of rhPDGF-BB in combination with a deproteinized bovine graft may have the potential to regenerated large three-dimensional alveolar defects in humans.

The article renders very nice photo and radiographich images of the post-treatment ridge forms and demonstrates, at least on two patients with limited follow-up, that vertical ridge augmentation in the mandibular arch may be possible under these special conditions.

Download Article


 
CTMAX Learning Center
© 2024 - CTMAX Learning Center